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Abstract
There is increasing evidence suggesting that the neuro-
transmitter Á-aminobutyric acid (GABA) is a local factor
involved in the regulation of endocrine organs. Examples
of such functions are documented in the pancreas, but
recent results suggest that GABA may act in a similar way
in the pituitary, in which GABA receptors are expressed
and pituitary growth hormone (GH) cells provide a source
of GABA. We hypothesised that GABA secreted in soma-
totropes may act as an autoregulatory signaling mole-
cule. To test this hypothesis we first examined the nature
of GABA receptors expressed by GH cells. RT-PCR analy-
sis demonstrated that GABA-B receptor subunits R1 and
R2 are present in the whole rat pituitary. Laser microdis-
section of immunostained GH cells, followed by RT-PCR
as well as immunoelectron microscopy, showed that
GABA-B receptors are expressed on somatotropes. To
investigate GABA-B receptor function in somatotropes,
we used rat GH3 adenoma cells, which, like pituitary GH
cells, express GABA-B R1 and R2 (as assessed by RT-PCR
and immunoelectron microscopy) and produce GABA
(checked by high performance liquid chromatography).
After inhibition of endogenous GABA synthesis, GH pro-
duction was stimulated by baclofen, a chromatography).
After inhibition of endogenous GABA synthesis, GH pro-
duction was stimulated by baclofen, a GABA-B receptor
agonist. By contrast, blocking GABA-B receptors by an
antagonist, phaclofen, decreased GH levels. We conclude
that in GH-producing cells, GABA acts as an autocrine fac-
tor via GABA-B receptors to control GH levels.
Copyright © 2002 S. Karger AG, Basel
Introduction
Production and secretion of hormones in the pituitary
is controlled by several hypothalamic factors. Besides the
classic releasing and inhibitory factors synthesised by the
hypothalamus, the neurotransmitter Á-aminobutyric acid
(GABA) regulates the production of pituitary hormones,
including corticotropin (ACTH), growth hormone (GH),
thyreostimulating hormone (TSH), luteinizing hormone
(LH) and prolactin (PRL). The effects of GABA depend
on several factors, such as concentration, developmental
stage and experimental conditions, and may be mediated
either directly or indirectly [1–7]. In the hypothalamus,
for instance, GABA acts on neurons secreting releasing
factors [8, 9]. In addition, axons of GABAergic hypotha-
lamic neurons terminate on endocrine pro-opiomelano-
cortin (POMC) cells of the intermediate lobe of the pitu-
itary [10, 11]. Moreover, GABAergic neurons extend to
the median eminence, where GABA is secreted into portal
vessels and reaches the anterior pituitary.
GABA-B Receptors and GH Secretion Neuroendocrinology 2002;76:170–177 171
Recently, additional sites of GABA production have
been identified in GH cells of the anterior pituitary and
POMC cells of the intermediate lobe in rat and monkey
pituitaries [12]. The same report showed that GH cells are
immunoreactive for a GABA-A receptor subunit (Á2).
These findings, together with the fact that all classes of
GABA receptors (A, B, C) were found to be present in the
anterior lobe [12–18], imply that GABA may exert auto-
crine actions within the adenohypophysis. This action
appears to include regulation of GH, as seen, for example,
in rats [3, 7, 16]. However, neither the mechanisms of
action of endogenous GABA nor its consequences for GH
cell function are currently known.
In order to define the role of GABA secreted by somato-
tropes, we used a rat pituitary adenoma cell line, GH3 [19].
GH3 cells, like GH cells, are able to produce and store
GABA [12]. Therefore they represent a valuable model for
studying the role of GABA in GH-producing cells. The
present work demonstrates that GH3 cells express func-
tional GABA-B receptors involved in the regulation of GH
synthesis and secretion. A similar mechanism of regulation
of GH synthesis may occur in pituitary GH cells, since we
show that they also bear GABA-B receptors.
Methods
Animals
Pituitary glands were obtained from male and female Sprague-
Dawley rats that had been bred at the Technische Universität
München. According to our animal care guidelines, they were pain-
lessly killed under ether anaesthesia and their pituitaries, and in
some cases brains, were removed and either processed for paraffin-
embedding or electron microscopy, or they were frozen for RNA
extraction, as described previously [12].
Culture Procedures of Rat GH3 Cells
The general culture procedures applied to GH3 cells have been
described previously [20]. GH3 cells were grown in F12-DME (Sig-
ma, Deisenhofen, Germany) containing 10% fetal calf serum (FCS;
PAA Laboratories, Linz, Austria) in 60-mm diameter Petri dishes
purchased from Life Technologies (Rockville, Md., USA). They were
submitted to treatments with 10–4 or 10–5 M GABA receptors ago-
nists or antagonists (Tocris, Ballwin, Mo., USA) before reaching con-
fluency. Unless otherwise stated, the treatments using two different
concentrations of chemicals gave similar results and thus were
pooled. These results were confirmed by a different handling proce-
dure that included a 24-hour starvation step (without FCS) for syn-
chronising the cells, followed by an additional day of culture in F12-
DME +2.5% FCS. The chemicals were subsequently added to the
2.5% FCS-containing medium for the time of treatment. In some
experiments, blocking glutamic acid decarboxylase (GAD) was nec-
essary to prevent endogenous GABA synthesis by GH3 cells. To this
end, we used 100 ÌM of Á-acetylenic GABA (Sigma) [21].
Laser Microdissection of Rat Pituitary GH Cells
PALM® Robot-MicroBeam Technology (P.A.L.M. GmbH, Bern-
ried, Germany) was used for ‘non-contact’ laser microdissection of
GH-immunostained cells from rat pituitaries. The samples were pre-
pared following the guidelines of the manufacturer. Bouin-fixed, par-
affin-embedded sections were deparaffinised and immunostained
with an anti-GH antiserum (diluted 1:500; courtesy of Dr. Parlow,
NHPP, Torrance, Calif., USA) following immunohistochemical
methods previously described [12, 22, 23]. From these sections, sam-
ples were catapulted directly into the cap of a microfuge tube and
stored at –80°C in the RNAlater buffer (Qiagen, Hilden, Germany)
until RNA isolation, reverse transcription (RT) and PCR were per-
formed.
RNA Isolation and RT-PCR
RNA isolation from either GH3 cells or rat tissues were per-
formed using the RNeasy kit and the QIAshredder columns from
Qiagen. The method used for RT (using MMLV, Stratagene, La Jol-
la, Calif., USA) and 18-mer polydeoxythymidine primers has been
described previously [24–26]. PCR consisted of a 5-min hot start step
followed by 40 cycles: 94°C for 30 s, 55°C for 1 min, 72 °C for 30–
60 s; final extension for 10 min at 72°C.
From laser microdissected samples, RNA was prepared using the
Purescript kit (Gentra Systems, Minneapolis, Minn., USA) and was
subsequently treated with DNase, precipitated and resuspended in
RNase-free water. This isolated RNA was reverse-transcribed using
Superscript II (Life Technologies) and random hexamers (MWG Bio-
tech, Ebersberg, Germany) according to the manufacturer’s instruc-
tions. For cDNA amplification, a nested PCR strategy was em-
ployed. A first PCR step (PCR1) was performed, the PCR1 product
was subsequently purified (MiniElute Kit, Qiagen) and used as tem-
plate for a second PCR. For all experiments, the nature of the ampli-
fied cDNAs was confirmed by direct sequencing using one of the
oligonucleotide primers (Agowa, Berlin, Germany).
Oligonucleotide primers were chosen to encompass exon-intron
boundaries to avoid possible genomic DNA contamination. Primers
designed for the R1 subunit do not distinguish between the splice
variants R1a and R1b. They were purchased from MWG Biotech
and their sequences are listed in table 1a, b. In addition a sense prim-
er (5)-GTA CGT CTG GTT CCT CAT-3)) was used in combination
with nested RI-3) for the analysis of GH3 and pituitary samples (see
fig. 2).
Electron Microscopy
GH3 cells and rat pituitaries were fixed on ice for 1 h with 2%
paraformaldehyde and 0.5% glutaraldehyde in 10 mM PBS, pH 7.4.
They were dehydrated with ethanol (30% at 0°C, 50% at –10°C,
70% at –30°C) and infiltrated at –30 °C with the hydrophilic resin
Lowicryl K4M (Plano, Wetzlar, Germany). Polymerisation was
achieved by exposure to ultraviolet light for 2 days at –30°C and for
3 days at room temperature, using an EM AFS apparatus from Leica
(Vienna, Austria). Following ultra thin sectioning, immunocyto-
chemistry was performed as described previously [27]. For immuno-
localisation of GABA-B R2, the primary antiserum was raised in rab-
bits and diluted 1:1,000 (courtesy of Graham Disney and Fiona Mar-
shall, GlaxoWellcome Research and Development, Stevenage, UK).
A secondary goat anti-rabbit antiserum was labelled either with
10-nm (immunostaining on GH3 cells) or 6-nm (double immuno-
staining on rat pituitaries) gold particles (diluted 1:20; Aurion, Wage-
ningen, The Netherlands). For immunodetection of GH, the first
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Table 1. Oligonucleotides used for RT-PCR
a Rat GABA-B R1a+b (Genbank accession No. Y10369 and Y10370) and positions of primers
R1–5) 5) CTGGCCTATGATGCTATC 3) 1402–1419 (R1a)/1054–1071 (R1b)
R1–3) 5) CGGAATGTCTTGATGACC 3) 1751–1734 (R1a)/1403–1386 (R1b)
Nested R1–5) 5) AACTACAACAACCAGACC 3) 1492–1509 (R1a)/1144–1161 (R1b)
Nested R1–3) 5) AGATCATCCTTGGTGCTG 3) 1676–1659 (R1a)/1328–1311 (R1b)
b Rat GABA-B R2 (accession No. AF058795) and positions of primers
R2–5) 5) CATCATCTTCTGCAGCAC 3) 2328–2345
R2–3) 5) TCTGTGAAGTTGCCCAAG 3) 2681–2664
Nested R2–5) 5) TCCAGTTCACACAGAACC 3) 2426–2443
Nested R2–3) 5) CCAGCTCTGTGATCTTCA 3) 2563–2546
antibody was raised in monkeys (diluted 1:500; courtesy of Dr. Par-
low, Torrance, Calif., USA) and the second antibody was a 10 nm
gold-labelled anti-human antibody (diluted 1:20; Aurion). Sections
were examined with the Zeiss electron microscope EM10.
Western Blotting
Western blotting was performed as described previously [28, 29].
In order to control small loading differences, Ponceau stainings of
separated proteins were performed. In addition, for some experi-
ments, ß-actin was detected and used as an additional reference pro-
tein. To this end, images were digitalised and optical densities of
Western blot results were evaluated using NIH Image, as described
previously [25].
For detection of GH, a monkey anti-GH primary antiserum (di-
luted 1:500) and peroxidase-conjugated goat anti-human immuno-
globulins were used (diluted 1:5,000; Jacksons Immunoresearch
Laboratories, West Grove, Pa., USA). Immunodetection of ß-actin
was achieved using a mouse anti-ß actin antibody purchased from
Sigma (diluted 1:5,000) and peroxidase-conjugated goat anti-mouse
immunoglobulins (diluted 1:5,000; Jacksons Immunoresearch Labo-
ratories). Results were visualised using an enhanced chemilumines-
cence kit (ECL; Amersham Pharmacia Biotech, Little Chalfont,
UK).
Enzyme Immunoassay
After treatment, the supernatants from confluent GH3 cells (4–
10 ! 106 cells) were harvested and stored at –20°C until use. In
order to measure the quantity of GH secreted by GH3 cells, a com-
mercial enzyme immunoassay (EIA) test was used (Biotrak system,
Amersham). GH levels were determined after reading the optical
density at 450 nm with a spectrophotometric plate reader (Dynex
Technologies, Chantilly, Va., USA). The values were finally ex-
pressed as ng GH. The sensitivity of the commercial test used was
1.7 ng/ml of GH.
High Performance Liquid Chromatography
As for the EIA, the supernatants from the GH3 cell cultures were
harvested after 24 h of treatment and stored at –20°C until use. The
culture medium was used as a reference. GABA analysis was carried
out by a high performance liquid chromatography (HPLC) method
with fluorimetric detection [30]. Briefly, amino acids were deriva-
tized with mercaptoethanol and o-phtalaldehyde (OPA). The OPA
derivatives were then separated on a 5-ÌM reverse-phase Nucleosil
C18 column (250 ! 4 mm; Macherey-Nagel, Duren, Germany), kept
at room temperature, using a mobile phase consisting of methanol
and potassium acetate (0.1 M, pH adjusted to 5.52 with glacial acetic
acid) at a flow rate of 1.0 ml/min in a three-linear step gradient (from
25 to 90% methanol). This method detects GABA quantities as low
as 100 fmol per volume injected. In the samples, GABA levels were
given as pmol/106 cells.
Statistical Analyses
For statistical data analyses, ANOVA and the Student-Newman-
Keuls multiple comparison test (Western blot results), or the Student
paired t test (HPLC and EIA data) were employed.
Results
GABA-B Receptor Subunits Are Expressed in
GH-Producing Cells of the Rat Pituitary and in 
GH3 Cells
Immunoelectron microscopy experiments, using dou-
ble immunostaining, identified GH-immunoreactive cells
to possess GABA-B R2 subunits at their membrane
(fig. 1a). The expression of R2 by GH cells was confirmed
at the mRNA level. To this end, rat pituitary sections
immunostained for GH were submitted to laser microdis-
section. RNA was extracted, RT-PCR experiments per-
formed and, using a nested PCR approach, the GABA-B
R2 subunit was detected in GH-immunoreactive cells.
GABA-B R2 was absent in samples in which GH-immu-
noreactive cells had been destroyed by a laser beam
(fig. 1b).
Both R1 and R2 subunits of the GABA-B receptor are
also expressed in cultured GH3 cells, as shown by RT-









Fig. 1. GH cells express GABA-B R2 subunit. a Immunoelectron
microscopy performed on an ultra thin section of a rat pituitary. The
nature of the cell shown was clearly identified by immunostaining of
GH-containing secretory granules (10-nm gold; bold arrow). At the
membrane of the GH cell, 6-nm gold labels indicate the presence of
GABA-B R2 subunit proteins (narrow arrow). Bar equivalent to
100 nm. b Section of a rat pituitary in which GH cells were identified
by immunohistochemistry and submitted to laser microdissection
(upper panel). Groups of GH-positive cells were separated from the
surrounding tissue by a laser beam (1a) and subsequently catapulted
(1b) inside the cap of a microfuge tube. To control false positives, all
GH cells (arrows) were destroyed in another area by laser shots
before laser excision (2). Bar equivalent to 80 Ìm. c RNA extracted
from laser-dissected pituitary GH cells was subsequently reverse
transcribed and submitted to nested PCR amplification. GH-pro-
ducing cells express GABA-B R2 (lane 1). No GABA-B R2 product is
detected after destroying GH cells in the surrounding tissue (lane 2).
Lane 3 is a control (PCR reaction without template). Lane 4 shows
the expression of R2 in the whole brain of a 4-week-old rat (positive
control). Sequencing of RT-PCR products confirmed their identity.
PCR and sequencing (fig. 2a). Furthermore, immunoelec-
tron microscopy showed localisation of the R2 subunit at
GH3 cell membranes (fig. 2b).
GABA Is Produced in GH3 Cells
Since GH3 cells have previously been shown to express
functional glutamic acid decarboxylase (GAD) and the
vesicular inhibitory amino acid transporter/vesicular
Á-aminobutyric acid transporter (VIAAT/VGAT) [12],
Fig. 2. GABA-B receptor subunits in GH3 cells. a RNA samples
extracted from GH3 cells and rat pituitary were reverse transcribed
and used for PCRs using specific primers for GABA-B receptors R1
and R2 subunits. Both subunits are expressed in GH3 cells and in
whole rat pituitary (Pit). Control experiments without template were
negative (not shown). Sequencing of RT-PCR products confirmed
their identity. b Immunoelectron microscopy experiments localised
the GABA-B R2 subunit protein at GH3 cell membrane (10-nm gold









HPLC measurements were now performed in order to
quantify GABA secretion by GH3 cells. The amount of
GABA released (B SEM) after 24 h was 1.72 B 0.54
nmol/106 cells (3 series of experiments, n = 5).
GABA-B Receptors Are Involved in the Control of GH
Production and Secretion by GH3 Cells
In order to examine the function of the GABA-B recep-
tors present in GH3 cells, the cultures were treated with
the GABA-B receptor antagonist phaclofen (pilot experi-
ments were run in order to identify efficient phaclofen
concentrations and the appropriate duration of treat-
ment). The cellular and extracellular GH levels in the
samples treated with phaclofen (10 or 100 ÌM for 24 h)
were compared with the ones of untreated controls. Cellu-
lar GH levels were analysed by SDS-PAGE and immuno-
blotting. The accuracy of the protein loading for the SDS-
PAGE was controlled by Ponceau staining of the mem-
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Fig. 3. Blockade of GABA-B receptors by phaclofen reduces GH pro-
duction in GH3 cells. In order to block GABA-B receptors, GH3 cells
were treated with phaclofen for 24 h. After treatment, proteins were
extracted and Western blots were performed to determine GH con-
tent. a A representative experiment is shown. The blockade of
GABA-B receptors resulted in a decrease of the GH content by pha-
clofen used at 10 or 100 ÌM (upper panel); ß-actin levels detected in
the same experiment were unchanged (lower panel), indicating equal
loading of the gel. b A graphical representation of 3 independent
experiments is depicted and shows a decrease in the GH content of
about 40%. Results are expressed as percent of untreated controls
(Co). Values are means + SEM. Differences between untreated and
treated samples were evaluated using ANOVA and Student-New-
man-Keuls tests; * p ! 0.05.
a
b





















Fig. 4. Activation of GABA-B receptors by baclofen stimulates GH
production in GH3 cells. An inhibitor of GABA synthesis (100 ÌM of
Á-acetylenic GABA) was added to the cell culture medium 2 h before
the supplement of baclofen (24 h). After treatment, proteins were
extracted and Western blots performed to analyse GH production.
Four independent experiments were performed. a As shown in the
upper panel, use of baclofen increased GH production. This was
observed in 3 of 4 experiments (no change was detected in 1 experi-
ment). ß-Actin levels were unchanged (lower panel), indicating equal
loading of the gel. b Activating GABA-B receptors led to a 29–47%
increase of GH content. A graphical representation of 3 experiments
showing similar results is given. GH contents are expressed as per-
cent of untreated control samples (Co). Values are means + SEM.
Differences between untreated and treated samples were evaluated
using ANOVA and Student-Newman-Keuls tests; * p ! 0.05.
a
b

























branes. Blocking of GABA-B receptors resulted in de-
creased GH content compared with untreated control
cells (n = 8). In some cases, GH values were normalised to
levels of a reference protein, ß-actin (n = 3). The values
obtained after optical density analysis of GH levels re-
vealed statistically significant decreases of about 40%
(fig. 3).
GH secretion was also modified by phaclofen treat-
ment, as shown by the results of the GH EIA. Superna-
tants of untreated cells of two different series of experi-
ments contained 27.39 B 3.01 ng GH (B SEM). Follow-
ing the blockade of GABA-B receptors by phaclofen, GH
levels were reduced by 60% (10.58 B 0.75 ng GH; p =
0.0023).
The samples used for the EIA and one additional series
of samples were also analysed by HPLC in order to deter-
mine GABA levels. The average amount of GABA re-
leased (B SEM) by untreated GH3 cells was 1.72 B
0.54 nmol/106 cells/24 h (n = 5). Like for GH, we ob-
served that GABA levels in the medium were decreased
by 20–80% in all samples treated with phaclofen (0.87 B
0.56 nmol GABA; p = 0.0022).
In 3 different experiments, consisting each of 2 control
samples and 2 samples treated with 100 ÌM of the GABA-
B receptor agonist baclofen, the cellular levels of GH were
analysed by SDS-PAGE and immunoblotting. The analy-
sis showed that direct activation of GABA-B receptors
increased GH levels. The accuracy of the protein loading
for the SDS-PAGE was controlled by Ponceau staining of
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the membranes and, in some cases, by immunoblotting
for a reference protein, ß-actin. The values obtained after
optical density analysis of GH levels were expressed as
percent of untreated control samples and showed statisti-
cally significant increases of GH levels, ranging from 29 to
47% (fig. 4). In order to avoid interference of endogenous
GABA produced by GH3 cells, a blocker of GABA syn-
thesis (100 ÌM of Á-acetylenic GABA) was added to the
culture medium 2 h before addition of baclofen for 24 h.
Discussion
The results of our study show that GH/GH3 cells pro-
duce GABA and express GABA-B receptors. We describe
that GABA, via GABA-B receptors, is involved in the
autocrine control of the GH cell phenotype.
GABA plays a role in the physiological regulation of
pituitary functions [1–7]. It is well established that GABA
is one of several signaling molecules involved in the con-
trol of GH production [3, 7, 31, 32]. GABA-affecting hor-
mone secretion by pituitary endocrine cells is produced in
the hypothalamus [8–11], but, as shown recently, also
within the pituitary itself, namely in POMC and in GH
cells [12]. GH3 cells are somatotropic cells derived from a
rat GH pituitary adenoma. They provide a well estab-
lished, widely used model for the study of the regulation
of GH and PRL production [19, 33]. Since our previous
results showed that GH3 cells produce GABA, we used
this cell line to investigate whether GABA derived from
GH-producing cells may contribute to the regulation of
GH synthesis and release. This mechanism of regulation
may involve all three different types of GABA receptors,
since evidence of their existence in the pituitary has been
provided [12–18, 34].
In the current study, we focussed on GABA-B recep-
tors. Their presence was recently confirmed at the molec-
ular level in the anterior lobe of rat pituitaries and in cells
derived from the mouse intermediate lobe [35, 36]. Re-
sults of the present study show that GABA-B receptors are
also expressed in a particular cell type of the anterior lobe
of the pituitary, the GH cell. Using laser microdissection
[37–39] of rat pituitary GH cells followed by RT-PCR, we
found that GH cells possess mRNA for GABA-B recep-
tors. This result was confirmed by immunoelectron mi-
croscopy.
Likewise, GH3 adenoma cells express GABA-B recep-
tor subunits, as shown in the present study, and were
therefore used to examine GABA-B receptor-mediated
events. To this end we blocked the action of GABA by
treating GH3 cells with the GABA-B antagonist phaclo-
fen. Phaclofen treatment led to a decreased GH content.
A reduction in GH levels in the medium, and thus pre-
sumably in GH release, was also measured. Results were
obtained using concentrations determined in pilot stud-
ies. We chose not to study dose-response relations, since
they appear questionable in a system in which GABA is
produced endogenously. Taken together, our results imp-
ly that levels of GH inside the cells and in the medium
were decreasing in parallel. We therefore hypothesise that
a role for GABA may be to maintain or increase GH pro-
duction via GABA-B receptors.
To examine this possibility further, endogenous
GABA synthesis was blocked by preventing the decarbox-
ylation of L-glutamate, using Á-acetylenic GABA [21],
before activation of GABA-B receptors by a GABA-B
receptor agonist, baclofen. Indeed, baclofen increased GH
content after 24 h of treatment, supporting our conclusion
that GABA regulates GH via GABA-B receptors.
These results obtained in a cell culture system are in
line with in vivo results showing an increase in GH secre-
tion following baclofen administration in humans [40,
41], or following GABA treatment in newborn rats [3, 31].
Therefore our results from GH3 cell and the localisation
of GABA-B receptors at the membrane of pituitary GH
cells are probably of relevance to mammalian species,
including humans, and highlight a novel aspect of GH cell
regulation.
Previously, we reported that VIAAT and GAD are
colocalised to secretory granules of GH cells [12], a result
suggesting corelease. Indeed, in the present study we pro-
vide evidence for cosecretion of GH and GABA, using
GH3 cells. Provided that pituitary GABA is released
together with GH, this may imply that GABA exerts an
autocrine positive feedback on GH cells. By acting on
GABA-B receptors, it may thus stimulate both GH pro-
duction as well as its own secretion.
GABA is mainly known for its synaptic role as a major
inhibitory neurotransmitter of the central nervous sys-
tem. That it can be produced and act in other, nonneuron-
al tissues is an emerging field. A role for GABA in endo-
crine tissues has been shown for the pancreas. There
GABA is cosecreted with insulin from ß-cells and in-
volved in the inhibitory action of glucose on glucagon
release by activating GABA-A receptors present in ·-cells
[42]. Our work in the pituitary and GH3 cells provides a
new example for an endocrine role of GABA acting as a
stimulatory autocrine regulator of GH production.
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